Therapeutic potential of medicinal marijuana: an educational primer for health care professionals
Abstract With the proposed Canadian July 2018 legalization of marijuana through the Cannabis Act, a thorough critical analysis of the…
Parkinson’s disease
Plasma Biomarkers Differentiate Parkinson’s Disease From Atypical Parkinsonism Syndromes
Abstract Objective: Parkinson’s disease (PD) has significant clinical overlaps with atypical parkinsonism syndromes (APS), which have a poorer treatment response…
Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor
Abstract Background: Neuroprotection with cannabinoids in Parkinson’s disease (PD) has been afforded predominantly with antioxidant or anti-inflammatory cannabinoids. In the…
Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats
Abstract Cannabidiol (CBD) is a non-psychotomimetic compound from Cannabis sativa that presents antipsychotic, anxiolytic, anti-inflammatory, and neuroprotective effects. In Parkinson’s…
Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection
Abstract Parkinson’s disease (PD) is a slow insidious neurological disorder characterized by a loss of dopaminergic neurons in the midbrain.…
Endocannabinoid–Dopamine Interactions in Striatal Synaptic Plasticity
Abstract The nigrostriatal dopaminergic system is implicated in action control and learning. A large body of work has focused on…
Cannabinoids and Dementia: A Review of Clinical and Preclinical Data
Abstract The endocannabinoid system has been shown to be associated with neurodegenerative diseases and dementia. We review the preclinical and…